Form 8-K - Current report:
SEC Accession No. 0001493152-25-005100
Filing Date
2025-02-06
Accepted
2025-02-06 09:00:23
Documents
15
Period of Report
2025-02-06
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 39542
2 ex99-1.htm EX-99.1 13412
3 ex99-1_001.jpg GRAPHIC 5295
  Complete submission text file 0001493152-25-005100.txt   240727

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE kapa-20250206.xsd EX-101.SCH 3027
5 XBRL LABEL FILE kapa-20250206_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE kapa-20250206_pre.xml EX-101.PRE 22367
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3801
Mailing Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064
Business Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064 818-404-5541
Kairos Pharma, LTD. (Filer) CIK: 0001962011 (see all company filings)

EIN.: 462993314 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42275 | Film No.: 25595632
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)